Reduced Serum sRAGE Levels Identify COPD and Reflect Disease Severity: Findings from a Cross-Sectional Study in India
Authors:
- Venkateshkumar Chandanna SeriVSVenkateshkumar Chandanna Seri
- Mohammed Kaleem UllahMUMohammed Kaleem Ullah
- Jayaraj Biligere SiddaiahJSJayaraj Biligere Siddaiah
- Sindaghatta Krishnarao ChayaSCSindaghatta Krishnarao Chaya
- Komarla Sundararaja LokeshKLKomarla Sundararaja Lokesh
- Suhail Azam KhanSKSuhail Azam Khan
- Aishwarya R. AladakattiAAAishwarya R. Aladakatti
- Shamnaz ShahulSSShamnaz Shahul
- Vivek VasanthanVVVivek Vasanthan
- Medha KarnikMKMedha Karnik
- SubbaRao V. MadhunapantulaSubbaRao V. Madhunapantula
- Swaroop RamaiahSRSwaroop Ramaiah
Open Access
- 17 November 2025
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 15 (22) , 2910
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) remains a leading cause of morbidity and mortality worldwide, particularly in low- and middle-income countries (LMICs), where both tobacco and biomass smoke exposure are major risk factors. While spirometry is the diagnostic gold standard, reliable non-invasive biomarkers are needed for early detection and disease monitoring. The soluble receptor for advanced glycation end-products (sRAGE), a circulating decoy receptor with anti-inflammatory activity, has shown potential in this context. Methods: In this prospective, exposure-stratified, cross-sectional study, 150 adults were enrolled into four groups of 25 each—tobacco-smoke COPD, male tobacco-exposed controls, biomass-smoke COPD, and female biomass-exposed controls—along with 50 healthy controls (25 males, 25 females). Participants underwent clinical evaluation, spirometry, and serum sRAGE quantification (ELISA). Systemic inflammation was assessed using neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Correlation and receiver operating characteristic (ROC) analyses determined diagnostic performance. Results: Serum sRAGE levels were significantly lower in tobacco-induced (545 ng/mL) and biomass-induced COPD (540 ng/mL) versus controls (1207–1462 ng/mL; p < 0.001). sRAGE correlated positively with FEV1, FVC, and FEV1/FVC (r = 0.54–0.75, p < 0.001), and negatively with CAT, mMRC, and SGRQ-C. ROC analysis showed excellent discrimination (AUC = 0.990; 94% sensitivity; 96% specificity at 946 ng/mL cutoff). Conclusions: Serum sRAGE is a robust, non-invasive biomarker for COPD diagnosis and severity assessment across exposure phenotypes. Its integration into clinical practice may enhance early detection and risk stratification, particularly in LMICs.Keywords
This publication has 30 references indexed in Scilit:
- An Integrative Genomic Strategy Identifies sRAGE as a Causal and Protective Biomarker of Lung FunctionChest, 2022
- Differences between cigarette smoking and biomass smoke exposure: An in silico comparative assessment of particulate deposition in the lungsEnvironmental Research, 2021
- Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet Respiratory Medicine, 2020
- The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary eventAtherosclerosis, 2019
- The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990–2016The Lancet Global Health, 2018
- Respiratory risks from household air pollution in low and middle income countriesThe Lancet Respiratory Medicine, 2014
- Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysisThorax, 2013
- Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysisThorax, 2011
- Chronic obstructive pulmonary disease in non-smokersThe Lancet, 2009
- Pathology, pathogenesis, and pathophysiologyBMJ, 2006